What Is Microdosing? The Complete Guide to Sub-Perceptual Psychedelics

In 2010, a psychologist named James Fadiman started collecting diaries. He asked people who microdosed psychedelics to write down what happened — not during the dose, because by design there was nothing dramatic to write about, but over the weeks and months that followed. What emerged was a picture that surprised him, and launched a global conversation about consciousness, productivity, and the nature of therapeutic change.

Fadiman had spent decades on the fringe of psychedelic research. He had been at Stanford in the 1960s when LSD was still legal and researchers were studying whether it could enhance creative problem-solving. That research was interrupted when psychedelics were criminalized in the late 1960s and early 1970s. When Fadiman returned to the subject forty years later, he wasn't interested in full-dose therapeutic sessions. He was interested in something subtler: what happens when you take one-tenth of a dose, not enough to hallucinate, just enough to shift something slightly, and then do it regularly for a month?

The reports that came back described improvements in mood, focus, and creativity. People said they were more present with their children. That long-stuck creative projects started moving. That the grinding background noise of anxiety had quieted somewhat. The reports were self-selected, uncontrolled, and scientifically inconclusive. But they were coherent enough to generate a hypothesis, and that hypothesis has been driving research ever since.

What Microdosing Actually Means

Microdosing is the practice of taking a sub-perceptual dose of a psychedelic compound on a regular schedule. Sub-perceptual means below the threshold where you notice you've taken something. No visuals, no altered sense of time, no dissolution of the ego. You should be able to go to work, drive a car, hold a normal conversation. The dose is small enough that if you didn't know you'd taken it, you might not notice.

The compounds most commonly used are psilocybin (from dried mushrooms) and LSD. Both are serotonergic psychedelics that act primarily on the 5-HT2A receptor. Both are Schedule I under the Controlled Substances Act, which means possession and use are illegal federally in the United States (with some state-level exceptions we'll get to).

Typical microdoses are:

• Psilocybin mushrooms: 0.1 to 0.3 grams of dried mushrooms, equivalent to roughly 1 to 3 milligrams of psilocybin
• LSD: 5 to 20 micrograms — approximately one-tenth to one-fifth of a typical full dose

The numbers matter less than the principle: you're looking for a dose that is active at the cellular level but quiet at the perceptual level. Getting there requires calibration. The "threshold" varies between individuals, between batches of mushrooms, and across the same person on different days depending on sleep, food, and baseline mood. Most practitioners start at the low end and adjust.

The Fadiman Protocol and Other Schedules

The Fadiman Protocol is the most widely referenced microdosing schedule. It looks like this: dose on day one, no dose on days two and three, then repeat. One day on, two days off, cycling continuously for four to eight weeks, then a break.

The rationale is pharmacological. Both psilocybin and LSD produce tolerance rapidly — meaning the second dose in quick succession produces a weaker effect than the first. Spacing doses three days apart prevents tolerance from accumulating. The off days are also observation days: you notice how you feel after the dose wears off, which is part of the data. Fadiman's protocol was designed to be rigorous enough to track effects while respecting the body's adaptive response.

Paul Stamets, the mycologist and fungi advocate, popularized a variation: four days on, three days off, and notably, he recommends stacking the microdose with two other compounds — lion's mane mushroom (Hericium erinaceus, believed to support nerve growth factor) and niacin (vitamin B3, which may help distribute the other compounds across the blood-brain barrier). The Stamets Stack is widely discussed in microdosing communities, though there's currently no clinical trial evidence specifically for the combination. Each component has its own research basis; the combined formulation does not.

Other practitioners use flexible schedules: microdose on specific days tied to workflow demands, or simply when mood dips below a personal baseline. These approaches are harder to study because there's no consistent variable to measure, but they reflect how most real-world microdosing actually happens — as a responsive practice rather than a rigid protocol.

What the Research Actually Shows

This is where the conversation gets complicated, and where anyone making strong claims needs to slow down.

The self-report literature is consistently positive. Survey studies involving thousands of microdosers consistently find that participants report improvements in mood, focus, creativity, productivity, and emotional regulation. These reports are coherent, widespread, and have been replicated across multiple research groups. A 2019 study by Vince Polito and Richard Stevenson tracked 98 microdosers over six weeks and found significant decreases in depression, stress, and distractibility alongside increases in neuroticism — a finding that appears in multiple datasets and may reflect heightened emotional sensitivity rather than instability.

Then come the placebo-controlled trials. And here the picture changes.

A 2021 study from Imperial College London, led by Balazs Szigeti, used a clever methodology: they partnered with existing microdosers in the community, asked them to prepare their own doses in opaque capsules, and then had participants blind themselves by randomly selecting from a bag of active and inactive capsules. The result was a "self-blinded" design that maintained naturalistic use while introducing uncertainty about what participants were taking on any given day.

The finding: when participants didn't know whether they'd taken an active or inactive capsule, the reported benefits largely disappeared. The expectation of benefit — the knowledge that you might be microdosing — appeared to be doing most of the work. The active compound produced minimal measurable advantage over placebo on cognitive performance tasks.

A 2022 pre-registered trial from the same group found similar results, with the addition that participants showed some evidence of increased anxiety on microdose days — a finding that runs counter to the popular narrative.

What this means practically: the placebo effect in microdosing appears to be substantial. That doesn't mean microdosing "doesn't work" — placebo responses are real responses, and if someone genuinely feels better, the mechanism matters less than the outcome in a certain practical sense. But it does mean the enthusiastic claims about microdosing as a cognitive or mood enhancer are running well ahead of the controlled evidence. Anyone citing the self-report literature as proof of efficacy is citing a population who knew they were microdosing. That's a fundamentally different claim.

Research is ongoing. The trials so far have been small, the dose protocols have varied, and the outcome measures have been inconsistent. The absence of strong evidence is not the same as evidence of absence. But we are not yet at the point where the science supports the hype.

Reported Benefits and Proposed Mechanisms

Setting aside the question of whether benefits are pharmacological or expectancy-driven, what do people report? The survey literature paints a consistent picture across thousands of respondents:

• Mood improvement: Reduced depression, reduced emotional reactivity, greater sense of equanimity. This is the most consistently reported benefit.
• Focus and productivity: Easier to enter flow states, better capacity to sustain attention on difficult tasks.
• Creativity: More novel associations, reduced mental rigidity, greater capacity to approach problems from new angles.
• Social ease: Reduced social anxiety, greater openness and empathy in conversations.
• Reduced anxiety: Particularly background anxiety or chronic low-grade stress, rather than acute situational anxiety.

The proposed mechanisms for why microdosing might produce these effects — if the effects are pharmacological rather than expectancy-based — draw on what we know about full-dose psychedelic neuroscience. 5-HT2A agonism increases neuroplasticity, including BDNF (brain-derived neurotrophic factor) expression and dendritic growth, in animal models. Even sub-threshold doses may produce some neuroplasticity signal. There's also evidence that psilocybin at low doses modulates the default mode network — the brain's resting-state self-referential system, which is overactive in depression and anxiety disorders.

Whether microdoses are sufficient to produce clinically meaningful neuroplasticity changes in humans is unresolved. The animal model doses don't translate directly to human microdosing protocols, and the human trials haven't yet found strong evidence of the proposed neuroplasticity mechanism in practice.

Risks and Considerations

Microdosing is not risk-free. The risks are different from those associated with full-dose psychedelic experiences — no acute psychological crisis risk at sub-perceptual doses — but they are real and worth understanding clearly.

Cardiac valvulopathy. Serotonin 5-HT2B receptors are found in cardiac tissue, and chronic activation has been associated with heart valve damage in long-term use of drugs that act on this receptor (notably some diet medications and MDMA at high doses). Psilocin has some 5-HT2B activity. Researchers have raised concern about whether long-term daily or near-daily microdosing could pose a cardiac risk. This is not established — there are no human studies demonstrating the effect at microdosing frequencies and durations — but it's the reason most researchers recommend against continuous daily microdosing and why protocols with rest days are considered more conservative.

Anxiety and emotional intensity. Microdosing appears to increase emotional sensitivity, which can manifest as heightened anxiety, irritability, or emotional reactivity in some individuals, particularly on dose days. People with anxiety disorders should approach with caution and ideally with clinical guidance.

Contraindications with medications. Combining psychedelics with serotonergic medications — SSRIs, SNRIs, MAOIs, lithium — is complex. SSRIs and SNRIs may blunt psychedelic effects through receptor downregulation; MAOIs can potentiate psychedelic effects dangerously. Anyone on psychiatric medication should not microdose without consultation with a knowledgeable prescriber. Lithium in combination with psychedelics has been associated with seizure risk.

Legal risk. This is not a pharmacological concern but it is a real one. Psilocybin and LSD are Schedule I federally. Possession is illegal regardless of dose. Certain states and cities have decriminalized psychedelics, and Oregon and Colorado have created licensed therapeutic frameworks. But decriminalization is not legalization, and a microdose carries the same legal exposure as a full dose in jurisdictions where possession is criminalized. Check the current legal landscape in your state before making decisions.

Lack of long-term data. There are no longitudinal studies of human microdosers spanning multiple years. The practice has existed at scale for roughly a decade. The long-term effects — on cognition, mood, brain structure, cardiac function — are genuinely unknown. That doesn't make microdosing obviously dangerous. It means we don't know.

How People Actually Microdose

In practice, microdosing communities have developed a body of folk knowledge about how to do this responsibly. The broad contours:

Start low and calibrate. The first dose should be at the lower end of the range — 0.05 to 0.1 grams of mushrooms, or 5 micrograms of LSD. Take it on a day with no demands. Notice what happens. If you notice perceptual changes, the dose is too high. If you notice nothing at all, the dose may be too low. Calibration takes a few cycles.

Journaling matters. The Fadiman protocol was designed around journaling for a reason. Sub-perceptual effects are subtle and easily attributed to other variables. Keeping a daily log of mood, energy, focus, sleep, and notable events makes patterns visible over time. Without tracking, you're flying blind.

Set and setting still apply, even at microdose. Where you are, what you're doing, what you're expecting — these influence even sub-perceptual doses. People who microdose before difficult social situations or stressful work environments sometimes report that the emotional amplification is unwelcome. Starting with lower-demand days gives you better observational conditions.

Take breaks. The protocols with rest periods aren't just about tolerance. They're about giving yourself periods of normal baseline to compare against. Without a baseline, you can't tell whether the microdose is doing anything.

Source matters. Psilocybin mushrooms vary in potency significantly between batches and even between different parts of the same mushroom. Dried weight is a rough proxy, not a precise measure. LSD is somewhat more consistent in pharmaceutical preparations, but street doses are notoriously unreliable. This is a material source of variability in any microdosing practice and one reason why clinical research standardizes formulations.

The Legal Landscape

Microdosing exists in a complicated legal gray zone that is actively shifting. Federally, psilocybin and LSD are Schedule I — possession is illegal regardless of dose or intent. That federal status has not changed.

At the state level, the picture is more varied. Oregon's Measure 109, passed in 2020, created a licensed psilocybin services program — supervised therapeutic use, not take-home microdosing, but a meaningful step toward regulated access. Colorado's Proposition 122 passed in 2022, creating a similar framework for supervised psilocybin and other psychedelic therapies. Several cities — Denver, Oakland, Washington D.C., Ann Arbor — have passed decriminalization measures that deprioritize enforcement of personal possession.

Decriminalization is not the same as legality, and it is not the same as regulated access. A decriminalized possession charge can still result in confiscation, civil fines, or adverse professional consequences. Anyone considering microdosing should understand the specific laws in their jurisdiction. Our interactive state laws map tracks the current status across all 50 states.

The clinical trajectory matters here too. If psilocybin moves through FDA approval for depression or anxiety disorders — which several research groups are working toward — the legal status will shift, and regulated microdosing products become more plausible. That process is measured in years, not months, and the outcome is not guaranteed. But the regulatory landscape is meaningfully different from what it was a decade ago.

What Microdosing Is Not

It's worth being direct about a few things the popular conversation sometimes obscures.

Microdosing is not a substitute for mental health treatment. The survey reports of mood improvement are encouraging as hypotheses, but they are not clinical evidence that microdosing treats depression, anxiety disorders, PTSD, or any other condition. Treating a mental health condition requires a diagnosis, a treatment plan, monitoring, and usually professional support. Microdosing without that context — particularly while discontinuing prescribed medications — carries genuine risk.

Microdosing is not the same as psychedelic therapy. Full-dose therapeutic sessions, conducted in clinical settings with trained guides and structured preparation and integration protocols, are producing some of the most significant clinical results in psychiatric research in decades. That work happens at doses that produce profound, often difficult experiences. The therapeutic mechanism appears to be inseparable from the depth of the experience. Microdosing, whatever its effects, is a different thing doing a different thing. Conflating the two misrepresents both.

And microdosing is not well understood. The researcher consensus, such as it exists, is that we need larger, better-designed trials with standardized formulations, clearer outcome measures, and longer follow-up periods before we can say with confidence what microdosing does and for whom. The practitioners and community have outpaced the science significantly. That's not a criticism of the practitioners — the science couldn't keep up because of the scheduling status — but it means the field is, at the moment, long on compelling anecdote and short on robust clinical evidence.

That will change. The scheduling environment is shifting, the clinical infrastructure for psychedelic research is more developed than at any point since the early 1970s, and there are several well-designed microdosing trials in progress. The evidence base five years from now will look substantially different from what exists today.

For now, if you're curious about the broader context of psychedelic research and how microdosing fits into it, the complete picture of psychedelics is a good place to start. If you want to understand the compounds most commonly microdosed, psilocybin and LSD each have their own detailed treatments. And if you want to know what's actually happening legally in your state, the laws map has the current picture.